Literature DB >> 10146959

Health economics in primary care in the UK: containment of drug costs.

T Walley1, R T Edwards.   

Abstract

Mesh:

Year:  1993        PMID: 10146959     DOI: 10.2165/00019053-199303020-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  24 in total

1.  Protecting the medical commons: who is responsible?

Authors:  H H Hiatt
Journal:  N Engl J Med       Date:  1975-07-31       Impact factor: 91.245

2.  "Mind the gap": reflections of an American health maintenance organisation doctor on the new NHS.

Authors:  J E Sabin
Journal:  BMJ       Date:  1992-08-29

3.  Economic evaluation of drugs: a UK pharmaceutical industry perspective.

Authors:  N Wells
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

4.  Economic evaluation of pharmaceuticals: science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

5.  Where is the wisdom...?

Authors:  R Smith
Journal:  BMJ       Date:  1991-10-05

Review 6.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

7.  The role of health economics.

Authors:  R Klein
Journal:  BMJ       Date:  1989-07-29

8.  The impact of controlled trials on the practice of medicine.

Authors:  T C Chalmers
Journal:  Mt Sinai J Med       Date:  1974 Nov-Dec

9.  The end of clinical freedom.

Authors:  J R Hampton
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-29

10.  Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs.

Authors:  R Knill-Jones; M Drummond; H Kohli; L Davies
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

View more
  9 in total

1.  A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 2.  Drug rationing in the UK National Health Service. Current status and future prospects.

Authors:  T Walley; A Haycox; S Barton
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 3.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

4.  Is there a need for an independent centre for pharmacoeconomics in the UK?

Authors:  T Walley; R T Edwards
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

5.  Therapeutic dilemmas. An approach to the management of expensive pharmaceutical advances.

Authors:  L Y Nishimura; R Shane
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 6.  Current prescribing in primary care in the UK. Effects of the indicative prescribing scheme and GP fundholding.

Authors:  T Walley; R Wilson; J Bligh
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

7.  The emerging government requirement for economic evaluation of pharmaceuticals.

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

8.  Drugs, money and society.

Authors:  T Walley
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

9.  Pharmacoeconomics: a challenge for clinical pharmacologists.

Authors:  T Walley; P Davey
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.